Hospital.Help

Foster City/California The semi-annual subcutaneous injection of the capsid inhibitor Lenacapavir has protected women in Africa so effectively against infection with the HIV virus that an ongoing phase 3 study on pre-exposure prophylaxis could be terminated prematurely. The results were recently announced by the manufacturer in a press release. The results are to be presented on July 24th at the World AIDS Congress in Munich…